National and Kapodistrian University of Athens
Αξιολόγηση αγγειογενετικών και ανοσολογικών παραγόντων σε ασθενείς με ηπατοκυτταρικό καρκίνο (ΗΚΚ) πριν και μετά από τοπικές ή συστηματικές θεραπείες
Abstract
dc:descriptionEvaluation of immunological factors in patients with hepatocellular carcinoma (HCC) before and after locoregional treatments. Background: The effect of transarterial embolization (TACE) on the immune response against HCC is still unclear. Considering the increasing importance of immune checkpoints in HCC immunity, we aimed to investigate the role of serum TIM-3 and PD-L1 in this context, evaluate their association with HCC staging and explore the effect of TACE on their levels. Methods: Patients with HCC of various etiologies were included. Serum TIM-3 and PD-L1 levels were measured by ELISA. Their association with HCC staging according to Barcelona Clinic Liver Cancer (BCLC) criteria was examined. In patients who were submitted to TACE, pre- and 1-week post-treatment levels were also measured and their association with response to therapy (mRECIST) was assessed. Results: We studied 53 patients (age 76±11yr, 71.7% males, 100% cirrhotic, 84.9% viral etiology) with BCLC stages: 0 (5.7%), A (33.9%), B (32.1%), C (22.6%), and D (5.7%). Baseline sTIM-3 levels were detectable in 52/53 (98%) HCC patients. The median values of sTIM-3 in patients according to BCLC stage were 132 pg/mL (Q25–75: 93–143 pg/mL) in BCLC 0, 171 pg/mL (Q25–75: 113–232 pg/mL) in BCLC A, 218 pg/mL (Q25–75: 108–339 pg/mL) in BCLC B, 425 pg/mL (Q25–75: 266–633 pg/mL) in BCLC C, and 2671 pg/mL (Q25–75: 234–5000 pg/mL) in BCLC D. The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). Serum TIM-3 levels were not associated with HCC etiology (p = 0.183). Serum PD-L1 was detectable in 9/53 patients (17%). The probability of PD-L1 detection was significantly associated with sTIM-3 levels (univariate logistic regression, p = 0.047). In 33 patients who underwent TACE, post-treatment sTIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE sTIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028).Conclusions: a) Serum TIM-3 levels were significantly associated with BCLC stage and were higher in the advanced cases, b) TACE caused an increase of serum TIM-3 values 1-week post-intervention, c) post-TACE serum TIM-3 values were higher in those who responded completely to treatment comparing to partial responders. These data suggest that TIM-3 immune checkpoint may have a role on anti-tumor immunity following TACE, setting a basis for combining chemoembolization and immunotherapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tampaki, Maria
- Ταμπάκη, Μαρία
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47701